MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

Search

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

10.52 13.12

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.15

Максимум

10.74

Ключови измерители

By Trading Economics

Приходи

915K

-11M

Служители

42

EBITDA

106K

-12M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+205.47% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

69M

797M

Предишно отваряне

-2.6

Предишно затваряне

10.52

Настроения в новините

By Acuity

8%

92%

5 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.07.2025 г., 17:03 ч. UTC

Значими двигатели на пазара

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2.07.2025 г., 15:18 ч. UTC

Значими двигатели на пазара

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2.07.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.07.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2.07.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2.07.2025 г., 21:01 ч. UTC

Придобивния, сливания и поглъщания

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2.07.2025 г., 21:01 ч. UTC

Придобивния, сливания и поглъщания

AT&T and TPG Close DIRECTV Transaction

2.07.2025 г., 20:26 ч. UTC

Печалби

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2.07.2025 г., 20:22 ч. UTC

Пазарно говорене

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2.07.2025 г., 20:13 ч. UTC

Пазарно говорене

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2.07.2025 г., 19:09 ч. UTC

Пазарно говорене

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2.07.2025 г., 19:08 ч. UTC

Пазарно говорене

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2.07.2025 г., 19:01 ч. UTC

Пазарно говорене

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2.07.2025 г., 18:08 ч. UTC

Пазарно говорене

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2.07.2025 г., 17:06 ч. UTC

Придобивния, сливания и поглъщания

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2.07.2025 г., 17:05 ч. UTC

Придобивния, сливания и поглъщания

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2.07.2025 г., 17:04 ч. UTC

Придобивния, сливания и поглъщания

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2.07.2025 г., 17:04 ч. UTC

Придобивния, сливания и поглъщания

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2.07.2025 г., 17:02 ч. UTC

Придобивния, сливания и поглъщания

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2.07.2025 г., 17:02 ч. UTC

Придобивния, сливания и поглъщания

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

2.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

2.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

2.07.2025 г., 16:11 ч. UTC

Пазарно говорене

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2.07.2025 г., 16:09 ч. UTC

Пазарно говорене

Gold Futures Rise, Recouping Some Losses -- Market Talk

2.07.2025 г., 15:59 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2.07.2025 г., 15:17 ч. UTC

Пазарно говорене

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2.07.2025 г., 15:08 ч. UTC

Пазарно говорене

Luxury Sector Should Report a Slowdown -- Market Talk

2.07.2025 г., 15:00 ч. UTC

Придобивния, сливания и поглъщания

Glencore: Merger of Viterra With Bunge Global Closed

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

205.47% нагоре

12-месечна прогноза

Среден 28.5 USD  205.47%

Висок 42 USD

Нисък 15 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

5 / 380 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.